|
|
Volumn 340, Issue , 2010, Pages
|
|
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CAPECITABINE;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
FLUOROURACIL;
LAPATINIB;
QUINAZOLINE DERIVATIVE;
BREAST TUMOR;
COST BENEFIT ANALYSIS;
DRUG RECALL;
ECONOMICS;
FEMALE;
HUMAN;
METASTASIS;
NOTE;
QUALITY ADJUSTED LIFE YEAR;
TREATMENT OUTCOME;
UNITED KINGDOM;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
COST-BENEFIT ANALYSIS;
DEOXYCYTIDINE;
DRUG RECALLS;
FEMALE;
FLUOROURACIL;
GREAT BRITAIN;
HUMANS;
NEOPLASM METASTASIS;
QUALITY-ADJUSTED LIFE YEARS;
QUINAZOLINES;
TREATMENT OUTCOME;
|
|
EID: 77954499870
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.c3145 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
